Abstract: A compound of formula I wherein A denotes a benzo, indolo or thieno group; R1 denotes thienyl or the group  wherein R7, R8 and R9 independently of one another may represent methyl, ethyl, propyl, phenyl or benzyl, while not more than 2 of the substituents can simultaneously represent phenyl or benzyl; R2, m, R3 and R4 are defined as in the specification, as well as pharmaceutical preparations containing this compound and the new pharmaceutical uses thereof.

Abstract: A compound of formula I wherein A denotes a benzo, indolo or thieno group; R1 denotes thienyl or the group wherein R7, R8 and R9 independently of one another may represent methyl, ethyl, propyl, phenyl or benzyl, while not more than 2 of the substituents can simultaneously represent phenyl or benzyl; R2, m, R3 and R4 are defined as in the specification, as well as pharmaceutical preparations containing this compound and the new pharmaceutical uses thereof.

Abstract: Compound of general formula I ##STR1## wherein A denotes a benzo, indolo or thienyl group;B denotes the group --O--, --S-- or --CHR.sup.5 --, wherein R.sup.5 is hydrogen, (C.sub.1 -.sub.6)alkyl, phenyl or benzyl;R.sup.3 denotes 2- or 3-thienyl, (C.sub.4 -.sub.7)cycloalkyl, (C.sub.4 -.sub.6)cycloalkyl(C.sub.1 -.sub.5)alkyl or ##STR2## wherein R is (C.sub.1 -.sub.4)alkyl, hydroxy, --N.sub.3, halogen (F, Cl, Br, I), CF.sub.3 or (C.sub.1 -.sub.4)alkoxy,u is 0, 1, 2 or 3, andm, R.sup.2, R.sup.4, R.sup.7, R.sup.8 and R.sup.9 are as defined in the specification, as well as pharmaceutical preparations containing these compounds and the pharmaceutical use thereof.

Abstract: The invention relates to the use of carbocyclically and heterocycally fused dihydroyridines as cerebroprotective agents, as agents for treating chronic inflammatory processes and as agents for inhabiting blood clotting, and also relates to new compounds of formula Ie ##STR1##

Abstract: Compound of general formula I ##STR1## wherein A denotes a benzo, indolo or thienyl group;B denotes the group --O--, --S-- or --CHR.sup.5 --, wherein R.sup.5 is hydrogen, (C.sub.1-6)alkyl, phenyl or benzyl;R.sup.3 denotes 2- or 3-thienyl, (C.sub.4-7)cycloalkyl, (C.sub.4-6)cycloalkyl(C.sub.1-5)alkyl or ##STR2## wherein R is (C.sub.1-4)alkyl, hydroxy, --N.sub.3, halogen (F, Cl, Br, I), CF.sub.3 or (C.sub.1-4)alkoxy,u is 0, 1, 2 or 3, andm, R.sup.2, R.sup.4, R.sup.7, R.sup.8 and R.sup.9 are as defined in the specification, as well as pharmaceutical preparations containing these compounds and the pharmaceutical use thereof.

Abstract: A compound of formula I ##STR1## wherein A denotes a benzo, indolo or thieno group;R.sup.1 denotes thienyl or the group ##STR2## wherein R.sup.7, R.sup.8 and R.sup.9 independently of one another may represent methyl, ethyl, propyl, phenyl or benzyl, whilst not more than 2 of the substituents can simultaneously represent phenyl or benzyl;R.sup.2, m, R.sup.3 and R.sup.4 are defined as in the specification, as well as pharmaceutical preparations containing this compound and the new pharmaceutical uses thereof.

Abstract: Compound of general formula I ##STR1## wherein A is a benzo or thieno group;R.sub.1 is (C.sub.4-6)cycloalkyl, (C.sub.4-6)cycloalkyl-(C.sub.1-5)alkyl or ##STR2## R.sup.2, m, R.sup.3, R.sup.4, R and u are defined as in the specification, and pharmaceutical preparations containing this compound and the new pharmaceutical uses thereof.

Abstract: A compound of formula I ##STR1## wherein A denotes a benzo, indolo or thieno group;R.sup.1 denotes thienyl or the group ##STR2## wherein R.sup.7, R.sup.8 and R.sup.9 independently of one another may represent methyl, ethyl, propyl, phenyl or benzyl, while not more than 2 of the substituents can simultaneously represent phenyl or benzyl;R.sup.2, m, R.sup.3 and R.sup.4 are defined as in the specification, as well as pharmaceutical preparations containing this compound and the new pharmaceutical uses thereof.

Abstract: New compounds of general formula (I) are provided: ##STR1## which are explained in the specification can be prepared by a variety of methods. The compounds may be used in pharmaceutical compositions.

Abstract: The invention relates to new pyridazino?4',5':3,4!-pyrrolo?2,1-a!isoquinolines of the formula ##STR1## and the physiologically acceptable salts thereof with acids and complex-forming agents, wherein X is O, S or NHO and R.sub.1, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8 and R.sub.9 are defined as in the specification, and pharmaceutical preparations containing these compounds.

Abstract: The invention relates to the use of carbocyclically and heterocyclically fused dihydropyridines as cerebroprotective agents, as agents for treating chronic inflammatory processes and as agents for inhibiting blood clotting, and also relates to new compounds of formula Ie ##STR1##

Abstract: The invention relates to the use of 9-amino-pyridazino-?4',5':3,4!pyrrolo?2,1-a!isoquinolines of the formula ##STR1## and the physiologically acceptable salts thereof with acids, bases and complexing agents for preparing agents for treating chronic inflammatory processes, ulcerative colitis and Crohn's disease, and for producing agents having an antiproliferative activity. The definitions of substituents R.sub.1 to R.sub.9 are given in the specification. The invention also relates to new compounds of general formula I which are also defined in the specification and their use as cerebroprotective agents.

Abstract: Compound of general formula I ##STR1## wherein A is a benzo or thieno group;R.sub.1 is (C.sub.4-6)cycloalkyl, (C.sub.4-6)cycloalkyl-(C.sub.1-5)alkyl or ##STR2## R.sup.2, m, R.sup.3, R.sup.4, R and u are defined as in the specification, and pharmaceutical preparations containing this compound and the new pharmaceutical uses thereof.

Abstract: The invention relates to the use of carbocyclically and heterocyclically fused dihydropyridines as cerebroprotective agents, as agents for treating chronic inflammatory processes and as agents for inhibiting blood clotting, and also relates to new compounds of formula Ie ##STR1##

Abstract: Compound of general formula I ##STR1## wherein A denotes a benzo, indolo or thienyl group;B denotes the group --0--, --S-- or --CHR.sup.5 --, wherein R.sup.5 is hydrogen, (C.sub.1-6)alkyl, phenyl or benzyl;R.sup.3 denotes 2- or 3-thienyl, (C.sub.4-7)cycloalkyl, (C.sub.4-6)cycloalkyl(C.sub.1-5)alkyl or ##STR2## wherein R is (C.sub.1-4)alkyl, hydroxy, --N.sub.3, halogen (F, Cl, Br, I), CF.sub.3 or (C.sub.1-4)alkoxy,u is 0, 1, 2 or 3, andm, R.sup.2, R.sup.4, R.sup.7, R.sup.8 and R.sup.9 are as defined in the specification, as well as pharmaceutical preparations containing these compounds and the pharmaceutical use thereof.

Abstract: Compound of general formula I ##STR1## wherein A is a benzo or thieno group;R.sub.1 is (C.sub.4-6)cycloalkyl, (C.sub.4-6)cycloalkyl-(C.sub.1-5)alkyl or ##STR2## R.sup.2, m, R.sup.3, R.sup.4, R and u are defined as in the specification, and pharmaceutical preparations containing this compound and the new pharmaceutical uses thereof.

Abstract: A circuit arrangement which comprises at least one stage which is to be fed by a source voltage from a common voltage source, at least one of these stages comprising a control signal generating circuit which can apply a control signal, to be derived from the source voltage, to a control signal output bus conductor which is common to all stages. A control signal input bus conductor can be connected to the control signal output bus conductor via a central bridge when the source voltage has a value within a first value range and which can be isolated from the control signal output bus conductor by the central bridge when the source voltage has a value within a second value range. Each stage includes a respective control circuit which can be connected to the control signal input bus conductor in order to receive the control signal and which can adjust the stage to a source voltage from the associated value range by application or interruption of the control signal.

Abstract: A circuit arrangement for the supply of emergency current in the case of a mains failure, comprises an electrolytic capacitor which is connected through a diode to a charging voltage which is higher than the required output voltage. The new current supply circuit arrangement avoids energy losses as far as possible and guarantees a sufficiently rapid availability of the energy to be stored in the electrolytic capacitor in that the capacitor charging voltage is derived from an auxialiary voltage source. In a further embodiment, a transistor is connected between the electrolytic capacitor and the output terminal of the current supply circuit and is operated in the inverse mode in order to precharge the electrolytic capacitor with a base charge. This current supply circuit arrangement can be used for the emergency current supply of microcomputer systems.

Abstract: A power supply circuit which includes a current limit circuit for limiting the inrush current when the power supply is switched on. The current limit circuit is coupled between a supply voltage at the input end of the power supply and a storage capacitor at the output end of the power supply. The current limit circuit includes a first semiconductor switch having a resistor in parallel with its switching path. In parallel with the control path of the first semiconductor switch is a parallel circuit that includes a first capacitor, a first resistor and the switching path of a second semiconductor switch. The control electrode of the second semiconductor switch is connected to a tap on a first voltage divider to which a second capacitor is connected in parallel. The switching path of a third semiconductor switch is connected parallel to the control path of the second semiconductor switch.

Abstract: Amino acid derivatives of general formula ##STR1## (the definitions of the various symbols being explained in the specification) are suitable for treating high blood pressure and for cardioprotection. The new compounds are prepared and used in the usual way.